2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1561

Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Abstract Number: 1990

Treatment Of ACUTE Gout In The Emergency Department Evaluated According To The 2012 American College Of Rheumatology Guidelines
Abstract Number: 1731

Treatment Of Innate Immune Arthritis With a Toll-Like Receptor 7 Agonist Requires Type I Interferon
Abstract Number: 2669

Treatment Of Knee Osteoarthritis Patients With Strontium Ranelate Reduces The Loss Of Cartilage Volume and Bone Marrow Lesions As Assessed By Magnetic Resonance Imaging: Data From The Phase III Strontium Ranelate Efficacy In Knee Osteoarthrtis Trial
Abstract Number: 884

Treatment Of Lupus Nephritis With Abatacept Plus Low-Dose Pulse Cyclophosphamide Followed By Azathioprine (the Euro-Lupus Regimen): Twenty-Four Week Data From a Double-Blind Controlled Trial
Abstract Number: 1171

Treatment Of Psoriasis Patients With IMO-3100 Shows Improvement In Gene Expression Patterns Of Meta-Analysis Derived-3 Transcriptome and IL-17 Pathway
Abstract Number: 2582

Treatment Of Pulmonary Hypertension In Scleroderma Patients With Restricitive Lung Disease.Observations From The Pulmonary Hypertension Assessment and Recognition Of Outcomes In Scleroderma Cohort
Abstract Number: 2027

Treatment Of Refractory Adult-Onset Still’s Disease With Abatacept : Report Of Five Cases
Abstract Number: 1421

Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Abstract Number: 1749

Treatment Strategies and Outcomes In Patients With Systemic Sclerosis and Acute Myocardial Infarction
Abstract Number: 705

Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts
Abstract Number: 1843

Treatment With Staphyloccocal Protein A Which Is Immuno-Modulatory In The Murine Collagen Arthritis Model, Does Not Increase Infection Severity In Murine Listeria Or Candida Challenge Models, In Contrast To Anti-TNF Treatment
Abstract Number: 1484

Treatment With The Glucagon-Like Peptide-1 Analogue Liraglutide Is Associated With Amelioration Of Disease Activity In a Prospective Cohort Study Of Patients With Inflammatory Arthritis
Abstract Number: 1064

Trends In Hospitalizations Due To Organ Damage In Patients With Systemic Lupus Erythematosus In Canada, 2006-2010
Abstract Number: 1756

Trends In Incidence and Mortality In Rheumatoid Arthritis and Systemic Autoimmune Rheumatic Diseases In Quebec, Canada: A Population-Based Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].